2 ASX biotech shares Bell Potter just upgraded to buy

These biotech shares could be high risk/high reward options.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

If you have a high tolerance for risk, then read on! That's because Bell Potter has just upgraded two ASX biotech shares to buy ratings this morning.

Here's why the broker is feeling upbeat about these high-risk stocks:

Genetic Signatures Ltd (ASX: GSS)

According to the note, the broker has upgraded this global molecular diagnostics company's shares to a speculative buy rating with a trimmed price target of 90 cents. This implies a 78% upside from current levels.

Bell Potter sees a number of catalysts on the horizon which it feels could give the ASX biotech share a major boost. The broker explains:

We upgrade our recommendation to Buy (Speculative) with valuation of $0.90. The key potential catalysts are FDA 510(k) clearance for the Gastrointestinal Parasite kit, US commercial launch, completion of Respiratory kit clinical trial and broader engagement within the domestic and European market.

Mesoblast Ltd (ASX: MSB)

Bell Potter has also upgraded this ASX biotech share to a speculative buy rating with a 58 cents price target. This suggests a potential upside of 57% for investors.

While the broker was disappointed with the company's FDA blow last month, it highlights that early paediatric approval for remestemcel-L in GvHD remains an option for the allogeneic cellular medicines developer.

Subject to successfully generating new data, the broker estimates the company could resubmit the Biological License Application in the first quarter of 2024 followed by a two-month review period from the US FDA.

However, the real driver of its upgrade was Mesoblast's valuation. It explains:

There are no changes to earnings and valuation remains unchanged at $0.58. We upgrade to Buy (Speculative) based on share price movement. The announcements discussed here are encouraging for a potential approval in FY24, however, markets are likely to remain unconvinced until the FDA provides an approval.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »